Microbiology and Immunology Department, Faculty of Pharmacy, Ain Shams University, African Union Organization St., Abbassia, Cairo, 11566, Egypt.
Department of Microbiology and Immunology, Faculty of Pharmacy, Galala University, New Galala City, Suez, Egypt.
Virol J. 2022 Oct 24;19(1):167. doi: 10.1186/s12985-022-01902-2.
The rise of the highly lethal severe acute respiratory syndrome-2 (SARS-2) as corona virus 2019 (COVID-19) reminded us of the history of other pandemics that happened in the last century (Spanish flu) and stayed in the current century, which include Severe-Acute-Respiratory-Syndrome (SARS), Middle-East-Respiratory-Syndrome (MERS), Corona Virus 2019 (COVID-19). We review in this report the newest findings and data on the origin of pandemic respiratory viral diseases, reservoirs, and transmission modes. We analyzed viral adaption needed for host switch and determinants of pathogenicity, causative factors of pandemic viruses, and symptoms and clinical manifestations. After that, we concluded the host factors associated with pandemics morbidity and mortality (immune responses and immunopathology, ages, and effect of pandemics on pregnancy). Additionally, we focused on the burdens of COVID-19, non-pharmaceutical interventions (quarantine, mass gatherings, facemasks, and hygiene), and medical interventions (antiviral therapies and vaccines). Finally, we investigated the nanotechnology between COVID-19 analysis and immune system boosting (Nanoparticles (NPs), antimicrobial NPs as antivirals and immune cytokines). This review presents insights about using nanomaterials to treat COVID-19, improve the bioavailability of the abused drugs, diminish their toxicity, and improve their performance.
高致死性严重急性呼吸系统综合征 2 型(SARS-2)作为冠状病毒 2019(COVID-19)的兴起,让我们想起了上世纪(西班牙流感)和本世纪发生的其他大流行病的历史,包括严重急性呼吸系统综合征(SARS)、中东呼吸系统综合征(MERS)、冠状病毒 2019(COVID-19)。我们在本报告中回顾了有关大流行呼吸道病毒疾病的起源、储存库和传播模式的最新发现和数据。我们分析了宿主转换所需的病毒适应和致病性决定因素、大流行病毒的致病因素、症状和临床表现。之后,我们得出了与大流行发病率和死亡率相关的宿主因素(免疫反应和免疫病理学、年龄以及大流行对妊娠的影响)。此外,我们还关注了 COVID-19 的负担、非药物干预(隔离、大规模集会、口罩和卫生)以及医疗干预(抗病毒疗法和疫苗)。最后,我们研究了 COVID-19 分析和免疫系统增强之间的纳米技术(纳米颗粒(NPs)、作为抗病毒药物和免疫细胞因子的抗菌 NPs)。本综述介绍了利用纳米材料治疗 COVID-19、提高滥用药物的生物利用度、降低其毒性以及提高其性能的见解。